Related references
Note: Only part of the references are listed.Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid
Laura Sowerby et al.
JAMA DERMATOLOGY (2017)
Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies
Shelley J. E. Hwang et al.
MELANOMA RESEARCH (2016)
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
Jarushka Naidoo et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence
Alice Pinc et al.
MOLECULAR THERAPY (2012)
Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid
G Mazzi et al.
TRANSFUSION AND APHERESIS SCIENCE (2003)
Share Paper
